Pentraxin‐3 modulates lipopolysaccharide‐induced inflammatory response and attenuates liver injury

Luis Perea, Mar Coll, Lucia Sanjurjo, Delia Blaya, Adil El Taghdouini, Daniel Rodrigo‐Torres, José Altamirano, Isabel Graupera, Beatriz Aguilar‐Bravo, Marta Llopis, Julia Vallverdú, Joan Caballeria, Leo A. van Grunsven, Maria‐Rosa Sarrias, Pere Ginès, Pau Sancho‐Bru – 19 April 2017 – Acute‐on‐chronic liver injury is characterized by an important inflammatory response frequently associated with endotoxemia. In this context, acute‐phase proteins such as Pentraxin‐3 (PTX3) are released; however, little is known about their role in chronic liver disease.

A simplified multivisceral transplantation procedure for patients with combined end‐stage liver disease and type 2 diabetes mellitus

Xiao‐Shun He, Shun‐Jun Fu, Qiang Zhao, Xiao‐Feng Zhu, Dong‐Ping Wang, Ming Han, Wei‐Qiang Ju, Yi Ma, Xing‐Yuan Jiao, Xiao‐Peng Yuan, An‐Bin Hu, Zhi‐Yong Guo – 19 April 2017 – In liver transplant patients with type 2 diabetes mellitus (DM), the disease worsens after transplantation because of longterm use of diabetogenic immunosuppressive drugs, making management of those patients a great challenge.

Treating fatty liver disease by modulating mitochondrial pyruvate metabolism

Jerry R. Colca, William G. McDonald, Kyle S. McCommis, Brian N. Finck – 18 April 2017 – Modifying the entry of pyruvate into mitochondria may provide a unique approach to treat metabolic disease. The pharmacology of a new class of insulin sensitizers directed against a newly identified mitochondrial target may treat many aspects of nonalcoholic steatohepatitis, including fibrosis. This commentary suggests treating nonalcoholic steatohepatitis through a newly identified mechanism consistent with pathophysiology. (Hepatology Communications 2017;1:193‐197)

Sofosbuvir‐based regimens for the treatment of chronic hepatitis C in severe renal dysfunction

Paula Cox‐North, Kelsey L. Hawkins, Sean T. Rossiter, Marie N. Hawley, Renuka Bhattacharya, Charles S. Landis – 18 April 2017 – Sofosbuvir (SOF) is a nonstructural 5B polymerase inhibitor with activity in all hepatitis C virus (HCV) genotypes and is the backbone of many anti‐HCV drug regimens. SOF is converted into inactive metabolites that undergo renal excretion.

Prevention and treatment of complications of selective internal radiation therapy: Expert guidance and systematic review

Bruno Sangro, Diego Martínez‐Urbistondo, Lourens Bester, Jose I. Bilbao, Douglas M. Coldwell, Patrick Flamen, Andrew Kennedy, Jens Ricke, Ricky A. Sharma – 13 April 2017 – Selective internal radiation therapy (or radioembolization) by intra‐arterial injection of radioactive yttrium‐90‐loaded microspheres is increasingly used for the treatment of patients with liver metastases or primary liver cancer. The high‐dose beta‐radiation penetrates an average of only 2.5 mm from the source, thus limiting its effects to the site of delivery.

Subscribe to